Refine
Has Fulltext
- yes (2)
Is part of the Bibliography
- yes (2)
Document Type
- Doctoral Thesis (2)
Language
- English (2)
Keywords
- G-Protein gekoppelte Rezeptor (2) (remove)
While life expectancy increases worldwide, treatment of neurodegenerative diseases such as AD becomes a major task for industrial and academic research. Currently, a treatment of AD is only symptomatical and limited to an early stage of the disease by inhibiting AChE. A cure for AD might even seem far away. A rethinking of other possible targets is therefore necessary. Addressing targets that can influence AD even at later stages might be the key. Even if it is not possible to find a cure for AD, it is of great value for AD patients by providing an effective medication. The suffering of patients and their families might be relieved and remaining years may be spent with less symptoms and restrictions.
It was shown that a combination of hCB2R agonist and BChE inhibitor might exactly be a promising approach to combat AD. In the previous chapters, a first investigation of dual-acting compounds that address both hCB2R and BChE was illustrated (figure 6.1).
A set of over 30 compounds was obtained by applying SARs from BChE inhibitors to a hCB2R
selective agonist developed by AstraZeneca. In a first in vitro evaluation compounds showed
selectivity over hCB1R and AChE. Further investigations could also prove agonism and showed
that unwanted off-target affinity to hMOP receptor could be designed out. The development of
a homology model for hCB2R (based on a novel hCB1R crystal) could further elucidate the
mode of action of the ligand binding. Lastly, first in vivo studies showed a beneficial effect of
selected dual-acting compounds regarding memory and cognition.
Since these first in vivo studies mainly aim for an inhibition of the BChE, it should be the aim
of upcoming projects to proof the relevance of hCB2R agonism in vivo as well. In addition,
pharmacokinetic as well as solubility studies may help to complete the overall picture.
Currently, hybrid-based dual-acting hCB2R agonists and selective BChE inhibitors are under
investigation in our lab. First in vitro evaluations showed improved BChE inhibition and
selectivity over AChE compared to tacrine.78 Future in vitro and in vivo studies will clarify their
usage as drug molecules with regard to hepatotoxicity and blood-brain barrier penetration.
Since the role of hCB2R is not yet completely elucidated, the use of photochromic toolcompounds
becomes an area of interest. These tool-compounds (and their biological effect) can
be triggered upon irradiation with light and thus help to investigate time scales and ligand
binding.
A set of 5-azobenzene benzimidazoles was developed and synthesized. In radioligand binding
studies, affinity towards hCB2R could be increased upon irradiation with UV-light (figure 6.2).
This makes the investigated compounds the first GPCR ligands that can be activated upon
irradiation (not vice versa).
The aim of upcoming research will be the triggering of a certain intrinsic activity by an
“efficacy-switch”. For this purpose, several attempts are currently under investigation: an
introduction of an azobenzene moiety at the 2-position of the benzimidazole core already led to
a slight difference in efficacy upon irradiation with UV light. Another approach going on in our
lab is the development of hCB1R switches based on the selective hCB1R inverse agonist
rimonabant. First in vitro results are not yet available (figure 6.3).
G protein-coupled receptor research looks out for new technologies to elucidate the complex
processes of receptor activation, function and downstream signaling with spatiotemporal
resolution, preferably in living cells and organisms. A thriving approach consists in making use
of the unsurpassed properties of light, including its high precision in space and time, noninvasiveness
and high degree of orthogonality regarding biological processes. This is realized
by the incorporation of molecular photoswitches, which are able to effectively respond to light,
such as azobenzene, into the structure of a ligand of a given receptor. The muscarinic
acetylcholine receptors belong to class A GPCRs and have received special attention in this
regard due to their role as a prototypic pharmacological system and their therapeutic potential.
They mediate the excitatory and inhibitory effects of the neurotransmitter acetylcholine and
thus regulate diverse important biological processes, especially many neurological functions in
our brain.
In this work, the application of photopharmacological tool compounds to muscarinic receptors
is presented, consisting of pharmacophores extended with azobenzene as light-responsive
motif. Making use of the dualsteric concept, such photochromic ligands can be designed to bind
concomitantly to the orthosteric and allosteric binding site of the receptor, which is
demonstrated for BQCAAI (M1) and PAI (M2) and may lead to subtype- and functionalselective
photoswitchable ligands, suitable for further ex vivo and in vivo studies.
Moreover, photoswitchable ligands based on the synthetic agonist iperoxo were investigated
extensively with regard to their photochemical behavior and pharmacological profile, outlining
the advantages and challenges of using red-shifted molecular photoswitches, such as tetraortho-
fluoro azobenzene. For the first time on a GPCR it was examined, which impact the
different substitution pattern has on both the binding and the activity on the M1 receptor. Results
show that substituted azobenzenes in photopharmacological compounds (F4-photoiperoxo and
F4-iper-azo-iper) not just represent analogs with other photophysical properties but can exhibit
a considerably different biological profile that has to be investigated carefully.
The achievements gained in this study can give important new insights into the binding mode
and time course of activation processes, enabling precise spatial and temporal resolution of the
complex signaling pathway of muscarinic receptors. Due to their role as exemplary model
system, these findings may be useful for the investigation into other therapeutically relevant
GPCRs.